BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38085895)

  • 61. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
    Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
    Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
    [TBL] [Abstract][Full Text] [Related]  

  • 63. CNS prophylaxis in lymphoma: who to target and what therapy to use.
    Hill QA; Owen RG
    Blood Rev; 2006 Nov; 20(6):319-32. PubMed ID: 16884838
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.
    Dufour J; Choquet S; Hoang-Xuan K; Schmitt A; Ahle G; Houot R; Taillandier L; Gressin R; Casasnovas O; Marolleau JP; Tamburini J; Serrier C; Perez E; Paillassa J; Gyan E; Chauchet A; Ursu R; Kas A; Soussain C; Houillier C
    Ann Hematol; 2023 May; 102(5):1159-1169. PubMed ID: 36991231
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Management of secondary central nervous system lymphoma.
    Cwynarski K; Cummin T; Osborne W; Lewis J; Chaganti S; Smith J; Linton K; Greaves P; McKay P; Fox CP;
    Br J Haematol; 2023 Jan; 200(2):160-169. PubMed ID: 36408800
    [No Abstract]   [Full Text] [Related]  

  • 67. Advances in therapeutic strategies for primary CNS B-cell lymphomas.
    Ramadan S; Radice T; Ismail A; Fiori S; Tarella C
    Expert Rev Hematol; 2022 Apr; 15(4):295-304. PubMed ID: 35467473
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.
    Ferreri AJ; Donadoni G; Cabras MG; Patti C; Mian M; Zambello R; Tarella C; Di Nicola M; D'Arco AM; Doa G; Bruno-Ventre M; Assanelli A; Foppoli M; Citterio G; Fanni A; Mulè A; Caligaris-Cappio F; Ciceri F
    J Clin Oncol; 2015 Nov; 33(33):3903-10. PubMed ID: 26282634
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
    Santambrogio E; Nicolosi M; Vassallo F; Castellino A; Novo M; Chiappella A; Vitolo U
    Expert Rev Hematol; 2019 Sep; 12(9):787-796. PubMed ID: 31305170
    [No Abstract]   [Full Text] [Related]  

  • 70. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
    Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
    Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Intraocular lymphoma: update on diagnosis and management.
    Chan CC; Wallace DJ
    Cancer Control; 2004; 11(5):285-95. PubMed ID: 15377987
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
    Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
    Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis.
    Epperla N; Reljic T; Chowdhury SM; Ferreri AJM; Kumar A; Hamadani M
    Hematol Oncol; 2023 Feb; 41(1):88-96. PubMed ID: 36192141
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature.
    Dholaria BR; Kumar A; Azzuqua AG; Nishihori T; Kharfan-Dabaja MA; Tun HW; Ayala E
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e273-e280. PubMed ID: 30914301
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Primary CNS lymphoma.
    Gerstner E; Batchelor T
    Expert Rev Anticancer Ther; 2007 May; 7(5):689-700. PubMed ID: 17492932
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
    Orellana-Noia V; Abousaud A
    Curr Treat Options Oncol; 2022 Oct; 23(10):1443-1456. PubMed ID: 36127571
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Diagnosis and treatment of primary CNS lymphoma.
    Korfel A; Schlegel U
    Nat Rev Neurol; 2013 Jun; 9(6):317-27. PubMed ID: 23670107
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CNS prophylaxis for diffuse large B-cell lymphoma.
    Eyre TA; Savage KJ; Cheah CY; El-Galaly TC; Lewis KL; McKay P; Wilson MR; Evens AM; Bobillo S; Villa D; Maurer MJ; Cwynarski K; Ferreri AJM
    Lancet Oncol; 2022 Sep; 23(9):e416-e426. PubMed ID: 36055310
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Have treatment protocols for primary CNS lymphoma advanced in the past 10 years.
    Seidel S; Schlegel U
    Expert Rev Anticancer Ther; 2019 Oct; 19(10):909-915. PubMed ID: 31594423
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.